Institutet för Hälso- och
Sjukvårdsekonomi
Box 2127
SE-220 02 Lund
Besök: Råbygatan 2
Tel: 046-32 91 00
ihe[at]ihe.se

Asseburg Christian
fil dr | projektledare

Arbetsområden

Christian Asseburg är bayesiansk statistiker som specialiserar sig på hälsoekonomiska modelleringer och evidenssyntes. Efter sin avhandling inom tillämpad statistik vid University of St Andrews i Skottland har Christian jobbad som hälsoekonom i England, Sverige och Finland. Från 2007 han har varit med i utvecklingen av IHE:s Economic and Health Outcomes Model for Diabetes (ECHO-T2DM). Efter fem år i Finland återvände Christian till IHE i februari 2015.


Urval av publiceringar

Willis M, Asseburg C, Nilsson A, Johnsson K & Kartman B
Multivariate Prediction Equations for HbA1c Lowering, Weight Change, and Hypoglycemic Events Associated with Insulin Rescue Medication in Type 2 Diabetes Mellitus: Informing Economic Modelling
Value in Health, 2017 Mar; 20 (3): 357-371
Published online: December 2016


Willis M, Johansen P, Nilsson A and Asseburg C
Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM)
PharmacoEconomics 2017; 35(3): 375-96
Publicerad online: 12 november 2016 


Andersson E, Asseburg C, Svensson J & Persson U
Nationella riktlinjer för vård vid multipel skleros (MS) och Parkinsons sjukdom – Stöd för styrning och ledning
Hälsoekonomiskt underlag till Remissversion 2016.
Stockholm: Socialstyrelsen 2016


Hallinen T, Soini E, Asseburg C, Kuosmanen P, Laakkonen A. Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary health care data. BMJ Open 2014;4:e004071. http://dx.doi.org/10.1136/bmjopen-2013-004071 (OPEN ACCESS)

Willis M, Asseburg C, He J. Validation of EConomic and Health Outcomes simulation model of Type 2 Diabetes Mellitus (ECHO-T2DM). Journal of Medical Economics 2013;16(8):1007-1021. http://dx.doi.org/10.3111/13696998.2013.809352

Theidel U, Asseburg C, Giannitsis E, Katus H. Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany. Clin Res Cardiol 2013;102(6):447-458. http://dx.doi.org/10.1007/s00392-013-0552-7 (OPEN ACCESS)

Ramsberg J, Asseburg C, Henriksson M. Effectiveness and cost-effectiveness of antidepressants in primary care -a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One 2012;7(8):e42003. http://dx.doi.org/10.1371/journal.pone.0042003 (OPEN ACCESS)

Asseburg C, Peura P, Oksanen T, Turunen J, Purmonen T, Martikainen J. Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison. International Journal of Technology Assessment in Health Care 2012;28(4):382-389. http://dx.doi.org/10.1017/S0266462312000517

Asseburg C, Willis M, Löthgren M, Seppälä N, Hakala M, Persson U. Hospitalisation utilisation and costs in schizophrenia patients in Finland before and after switch to risperidone long-acting injection. Schizophrenia Research and Treatment 2012, Article 791468:1-9. http://dx.doi.org/10.1155/2012/791468 (OPEN ACCESS)

Manca A, Asseburg C, Bravo Vergel Y, Seymour MT, Meade A, Stephens R, Parmar M, Sculpher MJ. The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS). Value Health 2012;15:22-31. http://dx.doi.org/10.1016/j.jval.2011.07.008

Purmonen TT, Pänkäläinen E, Turunen JH, Asseburg C, Martikainen JA. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol 2011;50:344-52. http://dx.doi.org/10.3109/0284186X.2011.553841 (OPEN ACCESS)

Smout S, Asseburg C, Matthiopoulos J, Fernández C, Redpath S, Thirgood S, Harwood J. The functional response of a generalist predator. PLoS One 2010;5:e10761. http://dx.doi.org/10.1371/journal.pone.0010761 (OPEN ACCESS)

Hjalte F, Asseburg C, Tennvall GR. Cost-effectiveness of a barrier-strengthening moisturizing cream as maintenance therapy vs. no treatment after an initial steroid course in patients with atopic dermatitis in Sweden – with model applications for Denmark, Norway and Finland. J Eur Acad Dermatol Venereol 2010;24:474-80. http://dx.doi.org/10.1111/j.1468-3083.2009.03449.x

Wailoo AJ, Goodacre S, Sampson F, Alava MH, Asseburg C, Palmer S, Sculpher M, Abrams K, de Belder M, Gray H. Primary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction: an economic analysis of the National Infarct Angioplasty Project. Heart 2010;96:668-72. http://dx.doi.org/10.1136/hrt.2009.167130

Bravo Vergel Y, Hawkins NS, Claxton K, Asseburg C, Palmer S, Woolacott N, Bruce IN, Sculpher MJ. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology 2007;46:1729-35. http://dx.doi.org/10.1093/rheumatology/kem221 (OPEN ACCESS)

Colbourn TE, Asseburg C, Bojke L, Philips Z, Welton NJ, Claxton K, Ades AE, Gilbert RE. Preventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses. British Med J 2007;335:655-8. http://dx.doi.org/10.1136/bmj.39325.681806.AD (OPEN ACCESS)

Bravo Vergel Y, Palmer S, Asseburg C, Fenwick E, de Belder M, Abrams K, Sculpher M. Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis. Heart 2007;93:1238-43. http://dx.doi.org/10.1136/hrt.2006.111401 (OPEN ACCESS)

J Matthiopoulos, K Graham, S Smout, C Asseburg, Redpath S, Thirgood S, Hudson P, Harwood J. Sensitivity to assumptions in models of generalist predation on a cyclic prey. Ecology 2007;88:2576-86. http://dx.doi.org/10.1890/06-0483.1

URVAL AV PRESENTATIONER

Traditional Risk Factors in T2DM Modeling: An Example Using Statins and the UKPDS 82 Outcomes Model”, Presented at Economics, simulation modelling & diabetes: The Mt Hood 2016 Challenge, St. Gallen, Switzerland, September 17-18, 2016. Johansen P, Willis M, Nilsson A, Asseburg C and Neslusan C

Asseburg C. "Position in treatment sequence can determine cost-effectiveness: An example from multiple sclerosis." Presented at the European Health Economics Association Conference 2016, Hamburg, Germany, July 14-16, 2016.

Neslusan C, Willis M, Johansen P, Schroeder M, Nilsson A, Chan E, Asseburg C, Schubert A. “The Role of Estimated Glomerular Filtration Rate (eGFR) in Cost-Effectiveness (CE) Analyses Using Canagliflozin (CANA) vs Sulfonylurea (SU) to Treat Type 2 Diabetes Mellitus (T2DM)”. Presented at ADA 76th Scientific Sessions, New Orleans, LA, USA, June 10-14, 2016.

Asseburg C, Willis M, Johansen P, Nilsson A, Neslusan C, Schroeder M. "Update of the Model Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM)”. Presented at ISPOR 21st Annual International Meeting, Washington, WA, USA, May 21-25, 2016.

Willis M, Neslusan C, Martin S, Johansen P, Asseburg C, O’Brien D. "Threshold-Based Metrics May Not Value All Benefits of Improved HbA1c: Implications for Health Care Resource Allocation”. Presented at International Diabetes Federation - World Diabetes Congress, Vancouver, Canada, November 30 – December 4, 2015.

Asseburg C, Johansen P, Nilsson A, Willis M. "Impact of the Framingham Offspring Study (FOS) vs. Kaiser Permanente Northwest (KPNW) prediction equations for diabetes mellitus in economic modelling of T2DM". Poster presented at the 51st EASD Annual Meeting, Stockholm, Sweden, 14-18 September 2015.

© IHE 2017